MINI REVIEW ARTICLE
published: 17 May 2012
doi: 10.3389/fgene.2012.00082

The path to microRNA therapeutics in psychiatric and
neurodegenerative disorders
Anthony W. S. Chan 1,2 and Jannet Kocerha 1,2 *
1
2

Yerkes National Primate Research Center, Atlanta, GA, USA
Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA

Edited by:
Michael Rossbach, Genome Institute
of Singapore, Singapore
Reviewed by:
Gerard J. Nuovo, Ohio State
University Medical Center, USA
Angela Pearson, INRS-Institut
Armand-Frappier, Canada
*Correspondence:
Jannet Kocerha, Yerkes National
Primate Center, Emory University,
954 Gatewood Road North East,
Atlanta, GA 30329, USA.
e-mail: jannet.kocerha@emory.edu

The microRNA (miRNA) class of non-coding RNAs exhibit a diverse range of regulatory roles
in neuronal functions that are conserved from lower vertebrates to primates. Disruption of
miRNA expression has compellingly been linked to pathogenesis in neuropsychiatric and
neurodegenerative disorders, such as schizophrenia, Alzheimer’s disease, and autism. The
list of transcript targets governed by a single miRNA provide a molecular paradigm applicable for therapeutic intervention. Indeed, reports have shown that speciﬁc manipulation of a
miRNA in cell or animal models can signiﬁcantly alter phenotypes linked with neurological
disease. Here, we review how a diverse range of biological systems, including Drosophila,
rodents, and primates such as monkeys and humans, can be integrated into the translation
of miRNAs as novel clinical targets.
Keywords: microRNAs, psychiatric, neurodegeneration, non-coding RNA, therapeutics, schizophrenia, monkeys, primates

INTRODUCTION
The multi-functional role of RNA as a molecular regulator spans
a broad range of classiﬁcations as protein-coding and non-protein
coding RNA transcripts. Notably, the microRNA (miRNA) class
of non-coding RNAs have been implicated in a vast majority of
the established signaling cascades (Bartel, 2009). Brain-localized
miRNAs are of particular interest for neurological diseases which
have a complex etiology and no currently effective therapeutic
options. The transcriptomic targets of an miRNA can encompass
numerous cellular pathways, consistent with the extensive molecular disruption linked to neurological disease onset. In this review,
we discuss how various model systems can be integrated into the
translation of miRNAs as novel clinical targets in the treatment of
neuropsychiatric and neurodegenerative disorders.
CONSERVED ROLE OF NEURONAL miRNAs
The conserved role of miRNAs in neuronal functions underscores
their relevance in the molecular dynamics between normal and
pathogenic mechanisms. Indeed, Drosophila, rodents, monkeys,
and humans have all shown signiﬁcant sensitivity to microRNA
modulation (Jin et al., 2004; Ashraf et al., 2006; Elmen et al.,
2008; Hollander et al., 2010). Notably, some core components of
the miRNA processing machinery, guided by the RNA-induced
silencing complex (RISC), are shared between lower vertebrates
and primates, such as the Argonaute-interacting proteins, GW182
(Chekulaeva and Filipowicz, 2009; Chekulaeva et al., 2011) and the
5 pocket motif of the Dicer-homologs (Park et al., 2011). Furthermore, regulation of long-term memory processes and associated
synaptic proteins are controlled by the miRNA RISC pathway in a
diverse group of species (Ashraf et al., 2006; Rajasethupathy et al.,
2009; Gao et al., 2010; Konopka et al., 2010). Collectively, the previous reports indicate that epigenetic modulation by miRNAs are a
principal component to central nervous system development and
homeostasis.

www.frontiersin.org

Several of the more extensively reported brain-enriched miRNAs, such as miR-9, miR-34, miR-124, miR-128, miR132, miR-219,
have predominantly identical mature sequences across species,
including humans, monkeys, mice, and Drosophila (Kapsimali
et al., 2007; Hu et al., 2011; Juhila et al., 2011). The conservation of those miRNAs spans from the 5 seed region to the 3 end
of the transcript. Moreover, the precursor sequence for some of the
brain-enriched miRNAs, including miR-9 and miR-124, are also
identical between humans and mice, further supporting a highly
conserved function for those transcripts.

miRNA REGULATION IN NEUROPSYCHIATRIC AND
NEURODEGENERATIVE DISORDERS
In the past few years, an extensive list of published reports have
emerged to support a signiﬁcant role for miRNAs in the pathogenesis of psychiatric and neurodegenerative disease (Bilen et al., 2006;
Lukiw, 2007; Hebert et al., 2008, 2009; Li et al., 2008, 2011; Wang
et al., 2009, 2010, 2011; Beveridge et al., 2010; Nelson and Wang,
2010; Nunez-Iglesias et al., 2010; Shioya et al., 2010; Chandrasekar
and Dreyer, 2011; Kocerha et al., 2011; Lee et al., 2011; Santarelli
et al., 2011; Smith et al., 2011; Liu et al., 2012b). The pathogenic
mechanisms underlying the development of psychiatric deﬁcits
and neurodegeneration are not always distinct, suggesting they
may be ideally suited for therapeutic targeting by pleiotropic miRNAs. Reports have shown that the precursor and mature miRNA
transcripts as well as the miRNA processing machinery itself, such
as Drosha and Dicer, are all subject to disruption with neurological disease progression (Sun et al., 2009; Beveridge et al., 2010;
Babiarz et al., 2011; Fenelon et al., 2011; Schoﬁeld et al., 2011).
Notably, the miRNA-linked pathology can be provoked through
either genetic or non-genetic (sporadic) anomalies (Rademakers
et al., 2008; Kocerha et al., 2011).
Schizophrenia, autism, Fragile X syndrome, depression, addiction, and anxiety are a few examples of psychiatric diagnoses where

May 2012 | Volume 3 | Article 82 | 1

Chan and Kocerha

MicroRNAs in neuropsychiatry and neurodegeneration

altered miRNA proﬁles have been identiﬁed, and a summary of the
dysregulated miRNAs and the biological source they were proﬁled
from are outlined in Table 1 (Jin et al., 2004; Abu-Elneel et al.,
2008; Li et al., 2008; Pietrzykowski et al., 2008; Hunsberger et al.,
2009; Yang et al., 2009; Zhou et al., 2009; Zhu et al., 2009; Beveridge
et al., 2010; Hollander et al., 2010; Im et al., 2010; Sarachana et al.,
2010; Saus et al., 2010; Xu et al., 2010a,b; Baudry et al., 2011a,b;
Eipper-Mains et al., 2011; Ghahramani Seno et al., 2011; Haramati
et al., 2011; Mouillet-Richard et al., 2011; O’Connor et al., 2011;
Shaltiel et al., 2012). In schizophrenia, miRNA proﬁling has now
been completed in several patient populations, primarily focused
within the cortex (Perkins et al., 2007; Beveridge et al., 2010; Kim
et al., 2010; Moreau et al., 2011; Santarelli et al., 2011). Although
a majority of the miRNA proﬁling studies for neurological disease have been performed from brain, miRNA dysregulation has
also been observed in other sources such as cerebral spinal ﬂuid

(CSF), plasma, serum, and peripheral blood (Schipper et al., 2007;
Cogswell et al., 2008; Gardiner et al., 2011; Ghidoni et al., 2011;
Lai et al., 2011). Beveridge and Cairns (2011) recently reviewed the
various studies to compare and contrast the collection of miRNA
results in schizophrenia. Interestingly, a few of the miRNA families, including the miR-15 and miR-30 families, have consistently
shown disruption in several of the population analyses (Beveridge
and Cairns, 2011). We examined the bioinformatic mRNA targets of miR-15 and miR-30 with Targetscan and found several
mRNAs which are strongly linked with schizophrenia, including neuregulin and synaptotagmin (Kim et al., 2007; Kao et al.,
2010).
Psychiatric symptoms can also co-exist in patients with neurodegenerative pathology, such as Huntington’s disease (HD),
Frontotemporal dementia (FTD), Alzheimer’s disease (AD),
Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS),

Table 1 | miRNAs associated with neuropsychiatric disease.
Disease

Associated miRNAs

Biological profiling source

Reference

Schizophrenia

106b, 107, 128a, 134, 150, 15a, 15b, 16, 17, 181a, 181b,

Human cortex (temporal and

Beveridge et al. (2008, 2010), Zhu et al.

195, 199a*, 19a, 20a, 20b, 212, 219, 24, 25, 26b, 27a,

prefrontal)

(2009), Perkins et al. (2007), Santarelli et al.

29a, 29b, 29c, 30a-5p, 30b, 30d, 30e, 328, 346, 382,

(2011)

487a, 9-3p, 92, let-7d, let-7e, 652, 7
219

Cortex from mouse model of

Kocerha et al. (2009)

schizophrenia
137, 30e

Human genomic DNA

Ripke et al. (2011), Xu et al. (2010a)

30e, 34a, 449a, 564, 432, 548d, 572, 652

Human blood

Xu et al. (2010a), Lai et al. (2011)

Schizophrenia

106b, 132*, 132, 133b, 138, 140-3p, 145*, 145, 148b,

Human cortex

Moreau et al. (2011), Kim et al. (2010)

or bipolar

151, 154*, 15a, 181a, 186, 190, 192, 193a, 193b, 210,

disorder

212, 22*, 22, 27b, 29a, 301, 32, 324-3p, 33, 330, 338,

Human cerebellum

Abu-Elneel et al. (2008)

Lymphoblastoid cell lines

Sarachana et al. (2010), Ghahramani Seno

339, 34a, 425, 454*, 504, 520c-3p, 544, 545, 573, 639,
7, 767-5p, 874, 889, 99a
Autism

106a, 106b, 128, 129, 132, 140, 146b, 148b, 15a, 15b,
181d, 193b, 21, 212, 23a, 27a, 320a, 381, 431, 432,
484, 539, 550, 598, 652, 7, 93, 95
103, 106b, 107, 10a, 125b, 132, 133b, 136, 139, 148b,
153-1, 16-2, 182-AS, 185, 186, 189, 190, 191, 194, 195,

et al. (2011)

196a, 199a-5p, 199b, 199b-5p, 205, 211, 219, 23a, 23b,
25, 29b, 30c, 326, 338-3p, 346, 367, 376a-AS, 451, 455,
455-3p, 486-3p, 486-5p, 495, 518a, 519c, 520b, 524,
577, 650, 93
Depression

16

Mouse

serotonergic

raphe

Baudry et al. (2011a,b)

nuclei
182, 30e

Human genomic DNA (blood)

Saus et al. (2010), Xu et al. (2010b)

101, 10a, 130a, 137, 142-3p, 142-5p, 146a, 148b, 155,

Human prefrontal cortex

Smalheiser et al. (2012)

Brain tissue from rat cocaine

Hollander et al. (2010), Chandrasekar and

addiction model

Dreyer (2011)

190, 20a, 20b, 27a, 301a, 324-5p, 335, 376a*, 489, 494,
497, 660
Addiction

212, 132, 124, let-7d, 181a
103, 125b-5p, 127, 138, 181a, 24, 26a, 29a, 29b, 30a,

Brain

30c, 30d, 30e, 7a, 7b, 7c, 7c, 9, let-7a, let-7f, let-7g

cocaine addiction model

9

tissue

from

mouse

Eipper-Mains et al. (2011)

Striatal neuronal cultures for

Pietrzykowski et al. (2008)

model of alcohol exposure
Anxiety

132, 34

Brain tissue from mouse model

Shaltiel et al. (2012), Haramati et al. (2011)

of anxiety

Frontiers in Genetics | Non-Coding RNA

May 2012 | Volume 3 | Article 82 | 2

Chan and Kocerha

all of which have shown miRNA disruption and is summarized
in Table 2 (Wang et al., 0000; Hebert et al., 2008; Packer et al.,
2008; Hebert and De Strooper, 2009; Williams et al., 2009; Haramati et al., 2010; Jiao et al., 2010; Lau and de Strooper, 2010;
Buckley and Johnson, 2011; Gaughwin et al., 2011; Kocerha
et al., 2011; Lee et al., 2011; Martins et al., 2011; MinonesMoyano et al., 2011; Smith et al., 2011; Enciu et al., 2012;
Mouradian, 2012). A pivotal role for miRNAs in neurodegenerative disease is further supported by numerous reports linking miRNAs with neurogenesis and neurodegenerative signaling
cascades, and thus, overall neuronal density (Patel et al., 2008;
Boissonneault et al., 2009; Gao, 2010; Magill et al., 2010; Schonrock et al., 2010; Shi et al., 2010; Cho et al., 2011; Shibata
et al., 2011; Tao et al., 2011; Han et al., 2012; Persengiev et al.,
2012).
Some miRNAs, such as miR-132, have been shown to be dysregulated in both psychiatric and neurodegenerative disease. miR-132
has been linked with schizophrenia (Perkins et al., 2007; Kim et al.,
2010), addiction (Hollander et al., 2010), HD (Lee et al., 2011),
AD (Cogswell et al., 2008), and progressive supranuclear palsy
(PSP; Smith et al., 2011). Indeed, the wide range of neurological diseases in which miR-132 is disrupted is consistent with its
principal role in neuronal plasticity and related functions (Magill
et al., 2010; Remenyi et al., 2010; Mellios et al., 2011; Shaltiel et al.,
2012).

NON-PRIMATE MODELS AND miRNA THERAPEUTIC
DISCOVERY
A selection of cell and animal models have been engaged in the
preliminary search for miRNAs with clinical relevance for neurological disease. Cell lines, primary cell cultures, differentiated
neurons, and induced pluripotent stem (iPS) cells are a few of the
platforms that have effectively been utilized for in vitro analyses
(Cole et al., 2008; Agostini et al., 2011; Arias-Carrion and Salama,
2011; Kim et al., 2011; Saba et al., 2012). Indeed, cell-based systems have led to successful large-scale screening studies as well as
in-depth molecular analysis of functional miRNAs (Vo et al., 2005;
Cole et al., 2008; Connelly et al., 2012). For example, the discovery
that neuronally enriched miR-132 is regulated by cAMP-response
element binding protein (CREB) was initiated through a genomewide screen in rat PC12 neuronal cells (Vo et al., 2005). Not all
miRNAs will have a functional biological role, however, cell-based
screens can facilitate the identiﬁcation of promising candidates.
In parallel with the in vitro ﬁndings, studies in non-primate
animal models have signiﬁcantly advanced our understanding
of miRNA biology in psychiatric and neurodegenerative disorders (Kocerha et al., 2009; Hollander et al., 2010; Lee et al.,
2011; Li et al., 2011). Animal studies are a critical step in
the progression toward testing of miRNA-based therapeutics in
clinical trials. Our group examined the regulation of miRNAs
in mice with pharmacological induction of a schizophreniaassociated behavioral phenotype (Kocerha et al., 2009). Likewise,
a neurotoxin induced mouse model (1-methyl-4-phenyl-1,2,3,6tetrahydropyridine; MPTP) for Parkinson’s disease (PD) was used
to uncover a role for miR-7 in PD pathology (Junn et al., 2009). In
addition to pharmacologically treated animal models, transgenic,
knock-out and knock-in mice have also been valuable in vivo

www.frontiersin.org

MicroRNAs in neuropsychiatry and neurodegeneration

resources (Lee et al., 2011; Tao et al., 2011). Indeed, transgenic
expression of the AD-causative amyloid precursor protein (APP)
gene in mice provoked signiﬁcant disruption in neuronal miRNA
expression (Schonrock et al., 2010).
In addition to mice, rats as well as zebraﬁsh and other vertebrate species have been integral in the study of neuronal miRNA
pathways prior to testing in primate models (Yang et al., 2011; Tal
et al., 2012). Indeed, recent reports identiﬁed miRNAs in zebraﬁsh
directly linked to neurobehavioral responses and neuronal differentiation (Tal et al., 2012). The exploration of miRNAs which
regulate central nervous system functions, however, is not limited to vertebrate species. Drosophila, an invertebrate model, have
been widely used for many years to examine or further deﬁne
molecular mechanisms. Moreover, studies in Drosophila recently
revealed that the conserved miRNA miR-34 mediates aging and
neurodegenerative processes (Liu et al., 2012a), further substantiating that all biological models are applicable in the investigation
of non-coding RNAs. Additionally, as each miRNA may regulate
a number of transcripts and therefore off-target effects may result
when altered, animal and cell models may help to ﬁlter out those
candidates.

PRIMATE MODELS AND miRNA PRE-CLINICAL EVALUATION
Arguably, a principal goal in the ﬁeld of non-coding RNAs, including miRNAs, is to uncover transcripts which can ultimately lead
to advancements in human health. Correspondingly, there are
numerous studies which have proﬁled miRNA expression from
humans with and without a disease diagnosis. Although some
of those reports have focused on peripheral tissues, a subset of
those analyses have speciﬁcally examined miRNA transcripts in
distinct brain regions (Hebert et al., 2008; Kocerha et al., 2011;
Santarelli et al., 2011). Genome-wide association (GWAS) studies
and microarray proﬁling have both been used to identify miRNAs
which are potential disease risk factors for neurodegenerative and
psychiatric disorders (Rademakers et al., 2008; Hollander et al.,
2010; Kocerha et al., 2011; Richardson et al., 2011; Ripke et al.,
2011). Furthermore, there can be disruption of a cluster or multiple members within an miRNA family, such as with miR-29. In
brain tissue from a cohort of Alzheimer’s patients, miR-29a and
miR-29b expression were both signiﬁcantly repressed in patients
with increased levels of beta-secretase/BACE1 (Hebert et al., 2008).
BACE1 is a direct mRNA target for the miR-29 family and has
consistently been linked to AD pathology. Therefore, correlation
of expression for a miRNA and its targets in the transcriptome,
as well as identiﬁcation of disruption in miRNA families, can all
contribute to effective discovery of new treatment alternatives for
diagnosed patients.
The brain structure and related functions of humans and monkeys are strikingly similar (King and Wilson, 1975; McConkey and
Varki, 2000; Paabo, 2001; Perkins et al., 2010; de Araujo et al.,
2012), suggesting that monkeys are a relevant primate model
for pre-clinical investigation of miRNAs in neurological dysfunction. Notably, certain key cell types in the brain linked to disease
pathology, such as mirror neuron disruption in autism (Perkins
et al., 2010), are primarily speciﬁc to primate physiology. Moreover, there is extensive conservation in miRNAs between primates,
including those which are localized in the central nervous system

May 2012 | Volume 3 | Article 82 | 3

Chan and Kocerha

MicroRNAs in neuropsychiatry and neurodegeneration

Table 2 | miRNAs associated with neurodegenerative disease.
Disease

Associated miRNAs

Biological profiling source Reference

Huntington’s

100, 125b, 127-3p, 135a, 135b, 138, 145, 146, 146a,

Huntington cell lines

Ghose et al. (2011), Sinha et al. (2010)

disease (HD)

148a, 150, 181c, 190, 199a-3p, 199a-5p, 200a, 205, 214,
34b

Human plasma

Gaughwin et al. (2011)

1-1, 124a, 128, 132, 133a, 135b, 138, 203, 204, 21, 218,

Brain tissue from trans-

Lee et al. (2011), Johnson et al. (2008)

22, 222, 29a, 29b-1, 29c, 330, 344, 346, 674*, 9-1, 9-3

genic HD mice

100, 151, 16, 219-2-3p, 27b, 451, 92a, 128, 139-3p, 222,

Human brain regions

Marti et al. (2010), Packer et al. (2008)

Human cortex and cerebel-

Kocerha et al. (2011)

218, 221, 222, 335, 338-3p, 9*, 9

382, 433, 485-3p, 9, 9*, 29b, 124a, 132
Frontotemporal

922, 516a-3p, 571, 548b-5p, 548c-5p

dementia (FTLD)

lum
29b, 107

Cell cultures

Wang et al. (2010), Jiao et al. (2010)

659

Human genomic DNA

Rademakers et al. (2008)

Parkinson’s dis-

1, 126*, 126, 147, 151-3p, 151-5p, 16-2*, 199a-3p, 19b,

Human blood

Martins et al. (2011), Margis and Rieder. (2011)

ease (PD)

22*, 26a, 26a2*, 28-5p, 29a, 29b, 29c, 301a, 30a, 30b,
30c, 335, 374a, 374b
34b, 34c, 133b

Human brain

Minones-Moyano et al. (2011), Kim et al. (2007)

50, 83, 58, 77, 238, 1, 48, 65, 64, 80, 84, let-7, 236, 51,

C. elegans

Asikainen et al. (2010)

10a, 10b, 212, 132, 495

Mouse model for PD

Gillardon et al. (2008)

let-7, 184*

Drosophila

Gehrke et al. (2010)

206

Mouse model for ALS

Williams et al. (2009)

137, 181c, 9, 29a, 29b, 34a, 181b

Human blood

Geekiyanage et al. (2011), Schipper et al. (2007)

137, 181c, 9, 29a, 29b

Human serum

Geekiyanage et al. (2011)

101, 106b, 107, 125b, 137, 142-3p, 142-5p, 145, 151-

Human cortex

Wang et al. (2011), Hebert et al. (2008), Shioya

241, 230,

Amylotrophic
lateral sclerosis
(ALS)
Alzheimer’s disease (AD)

5p, 15a, 181c, 184, 185, 194, 197, 19b, 210, 212, 214,

et al. (2010), Nelson and Wang (2010), Geekiyan-

219-2-3p, 22, 223, 26b, 27b, 298, 29a, 29a/b-1, 29b-1,

age and Chan (2011)

300, 301a, 320, 326, 330-5p, 338-3p, 338-5p, 361-3p,
363, 382, 424, 425, 509-5p, 511, 516a-5p, 516b, 525-5p,
551b, 576-5p, 583, 9, 93, 98, let-7e, let-7f, let-7i
9, 125b, 128, 124a

Human hippocampus

Lukiw (2007)

105, 10a, 10b, 125a, 126*, 126, 127, 135a, 138, 141,

Human CSF

Cogswell et al. (2008)

Human brain

Cogswell et al. (2008), Hebert et al. (2009),

142-5p, 143, 146b, 151, 154, 15b, 181a, 181c, 186, 191,
194, 195, 197, 199a*, 204, 205, 214, 216, 221, 302b,
30a-3p, 30a-5p, 30b, 30c, 30d, 32, 338, 345, 362, 371,
374, 375, 380-3p, 422b, 429, 448, 449, 451, 455, 494,
497, 501, 517a, 517b, 518b, 518f, 520a*, 526a, 7f, 99a
125b, 106b, 107, 124, 132, 145, 146b, 148a, 17-5p, 200c,
20a, 210, 212, 26a, 27a, 27b, 30c, 30e-5p, 34a, 381,

Smith et al. (2011), Wang et al. (2008)

422a, 423, 425, 9, 92, let-7b, 100
106a, 106b, 125b, 137, 146a, 147, 148b, 153, 17, 17-5p,

Cell cultures

Long and Lahiri. (2011), Kim et al. (2011), Bois-

181c, 187, 20a, 20b, 21, 212, 26a, 27a, 298, 301, 30b,

sonneault et al. (2009), Patel et al. (2008),

30c, 30e-5p, 323-3p, 328, 34a, 361, 365, 376b, 381,

Schonrock et al. (2010), Delay et al. (2011),

409, 422a, 423, 433, 520c, 644, 655, 664, 700, 7g, 7i,

Hebert et al. (2009), Smith et al. (2011)

9, 92
34a, 103, 107, 146a, 106b, 16, 34c, 20a, 17-5p

AD mice models
Yao et al. (2010), Li et al. (2011), Wang et al.
(2009, 2010), Liu et al. (2012b), Zovoilis et al.
(2011), Hebert et al. (2009)

214, 23a, 23b, 486-3p, 30e*, 143, 128, 27a, 27b,

Bioinformatic

324-5p, 422a

nucleotide

single

Mallick and Ghosh. (2011)

polymorphism

(SNP) analysis

Frontiers in Genetics | Non-Coding RNA

May 2012 | Volume 3 | Article 82 | 4

Chan and Kocerha

(Brameier, 2010; Hu et al., 2011). One recent study reported that
of the 413 miRNAs expressed in human brain, 366 of those transcripts are also detectable in rhesus macaque brain (Hu et al.,
2011). Correspondingly, a number of those miRNAs are also
detectable in mouse cortex and hippocampus by microarray and
sequencing efforts, such as miR-9, miR-124, miR-128, and miR132 (Juhila et al., 2011), suggesting that mouse models can be
effective prior to testing in primates.
There have been considerable technological advancements in
recent years with primate focused research, including with noncoding RNA biology. Groups have successfully delivered modiﬁedantisense oligonucleotides (ASO) into monkeys to inhibit the
function of speciﬁc miRNAs with minimal off-target effects
(Elmen et al., 2008; Petri et al., 2009; Lanford et al., 2010). To
date, the ability to modulate miRNAs in primates is restricted to
peripheral administration, however, delivery of potential therapeutics across the blood brain barrier could be a future attainable
milestone. Progress has also been made in other capacities with
primates, including with the generation of transgenic monkeys.
Our group established the ﬁrst transgenic rhesus macaques in
2001 (Chan et al., 2001), which subsequently led to the development of a cohort for HD transgenic monkeys (Yang et al.,
2008), a resource directly applicable to assess miRNA functions
in a primate model of neurodegenerative disease. Moreover, from
the HD monkeys we derived iPS cells which display a progressive cellular phenotype (Chan et al., 2010), providing an
in vitro platform to complement the in vivo analyses for therapeutic and biomarker discovery, including non-coding RNA
targets.
In primates, the progression of neurodegeneration and psychiatric deﬁcits is typically gradual, developing over years, rather
than weeks or months. Correspondingly, longitudinal analyses of
molecular and neurobehavorial changes are fundamental to the
monitoring and subsequent discovery of new treatments (Insel,
2009; Thompson et al., 2011). Indeed, longitudinal studies are
readily implementable in primate species such as monkeys and
humans, including collection of peripheral blood samples for
molecular analysis throughout disease progression and parallel
correlation with brain morphology by magnetic resonance imaging (MRI; Thompson et al., 2011; Waber et al., 2012; Zhang et al.,
2012). The correlation of miRNA expression with disease trajectories may help identify functional non-coding RNA transcripts
involved in neuronal pathogenesis.

APPROACHES FOR miRNA MODULATION AND CLINICAL
TRANSLATION
As discussed above, a considerable number of in vitro and in vivo
models are increasingly becoming available for miRNA functional studies. In conjunction, there have also been signiﬁcant
advances in the approaches to modulate or detect speciﬁc miRNAs.
Viral and antisense-mediated targeting of non-coding transcripts
are routinely applied to alter expression levels, however, technical improvements have allowed for increased effectiveness and
efﬁcacy. For example, locked nucleic-modiﬁed antisense oligonucleotides (LNA-ASO) signiﬁcantly enhance the speciﬁcity and
stability of miRNA silencing (Elmen et al., 2008; Stenvang et al.,
2008; Kocerha et al., 2009; Hollander et al., 2010; Obad et al., 2011).

www.frontiersin.org

MicroRNAs in neuropsychiatry and neurodegeneration

Notably, the LNA-ASO can be administered in vivo to animal
models through different routes, such as intracerebroventricular (icv) delivery to penetrate multiple brain regions (Kocerha
et al., 2009; He et al., 2010), or local stereotactic injections for
site-speciﬁc miRNA silencing (Gao et al., 2010; Hollander et al.,
2010). LNA-modiﬁed probes also intensify the detectability of
non-coding RNAs for in situ localization (Havelda, 2010), which
facilitates examination of less abundant transcripts. There are
other chemical modiﬁcations available for ASO, such as 2 -Omethyl RNA, 2 -O-methyloxyethyl RNA, and phosphorothioate
RNA (Ruberti et al., 2011), some of which have also been successfully utilized in the context of in vivo silencing (Cheng et al.,
2009).
In addition to viral and antisense methods, nanoparticle delivery of neurogenic miRNAs provide a means for brain distribution
of selected transcripts. Just recently, reports showed that rabies
virus glycoprotein (RGV)-labeled nanomaterials resulted in speciﬁc delivery of miR-124 to neuronal cells (Hwang do et al.,
2011). Nanotechnology has also been employed to silence miRNA
function, such as with miR-122 conjugated to gold nanoparticles in myeloma cells (Crew et al., 2012), suggesting this technology is effective in the repression or stimulation of miRNA
expression.
Importantly, silencing of miRNAs in animal embryos have
also provided signiﬁcant insight to their role in brain development. Recent reports have shown that injection of morpholinos to block miR-9 activity in the embryos of Xenopus tropicalis (Bonev et al., 2011) or zebraﬁsh (Tal et al., 2012) substantially altered neuronal functions in the developing animals.
Furthermore, overexpression or silencing of miR-9 via electroporation in mouse embryos revealed that Cajal Retzius neuronal
cell differentiation is regulated through Forkhead box protein
G1 (FOXG1; Shibata et al., 2008). Collectively, these reports
indicate that miRNA activity can be modulated in vivo at various developmental stages to assess their implications in brain
functions.
Overall, the technical developments in miRNA biology mentioned above facilitate the translation of select miRNA transcripts
for future clinical intervention. Indeed, there are human trials
currently being conducted to assess miRNA-modulation in disease pathogenesis, including the use of LNA-ASO (Seto, 2010;
Montgomery and van Rooij, 2011). To date, the reported human
trials have focused on miRNA regulation in peripheral organs,
however, therapeutic targeting of the brain remains a future objective. Polymer (Cheng and Saltzman, 2012), lipid (Shi et al., 2012),
and polylysine (Jin et al., 2012) based nanoparticle modulation
of miRNAs has also been reported. Although a majority of the
nanodelivery methods for miRNA studies have focused on nonneuronal cells, there is great potential for their application to the
central nervous system.

CONCLUSION
The discovery and development of miRNA-based therapeutics, as
well as the diverse range of molecular cascades they can regulate, offer a new approach for treating diseases with a heterogeneic
or epigenetic origin. There are numerous psychiatric and neurodegenerative diseases with no effective treatments due to their

May 2012 | Volume 3 | Article 82 | 5

Chan and Kocerha

MicroRNAs in neuropsychiatry and neurodegeneration

complex etiology and therefore may be ideally positioned for
clinical targeting of pleiotropic miRNAs.

ACKNOWLEDGMENTS
We thank Yerkes National Primate Research Center (YNPRC)
veterinarian and animal care staff in providing outstanding

REFERENCES
Abu-Elneel, K., Liu, T., Gazzaniga,
F. S., Nishimura, Y., Wall, D. P.,
Geschwind, D. H., Lao, K., and Kosik,
K. S. (2008). Heterogeneous dysregulation of microRNAs across the
autism spectrum. Neurogenetics 9,
153–161.
Agostini, M., Tucci, P., Steinert, J. R.,
Shalom-Feuerstein, R., Rouleau, M.,
Aberdam, D., Forsythe, I. D., Young,
K. W., Ventura, A., Concepcion, C.
P., Han, Y. C., Candi, E., Knight,
R. A., Mak, T. W., and Melino,
G. (2011). MicroRNA-34a regulates
neurite outgrowth, spinal morphology, and function. Proc. Natl. Acad.
Sci. U.S.A. 108, 21099–21104.
Arias-Carrion, O., and Salama, M.
(2011). Reprogramming neurons by
microRNAs into iPSCs to treat
Parkinson’s disease. Med. Hypotheses
77, 312–313.
Ashraf, S. I., McLoon, A. L., Sclarsic,
S. M., and Kunes, S. (2006). Synaptic protein synthesis associated with
memory is regulated by the RISC
pathway in Drosophila. Cell 124,
191–205.
Asikainen, S., Rudgalvyte, M., Heikkinen, L., Louhiranta, K., Lakso, M.,
Wong, G., and Nass, R. (2010).
Global microRNA expression proﬁling of Caenorhabditis elegans
Parkinson’s disease models. J. Mol.
Neurosci. 41, 210–218.
Babiarz, J. E., Hsu, R., Melton, C.,
Thomas, M., Ullian, E. M., and Blelloch, R. (2011). A role for noncanonical microRNAs in the mammalian
brain revealed by phenotypic differences in Dgcr8 versus Dicer1 knockouts and small RNA sequencing.
RNA 17, 1489–1501.
Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233.
Baudry, A., Mouillet-Richard, S.,
Schneider, B., Launay, J. M., and
Kellermann, O. (2011a). miR-16
a key for adaptive responses of
neurons to ﬂuoxetine. Med. Sci.
(Paris) 27, 128–131.
Baudry, A., Mouillet-Richard, S.,
Schneider, B., Launay, J. M., and
Kellermann, O. (2011b). miR-16
targets the serotonin transporter:
a new facet for adaptive responses
to antidepressants. Science 329,
1537–1541.

Beveridge, N. J., and Cairns, M. J.
(2011). MicroRNA dysregulation in
schizophrenia. Neurobiol Dis.
Beveridge, N. J., Gardiner, E., Carroll,
A. P., Tooney, P. A., and Cairns,
M. J. (2010). Schizophrenia is associated with an increase in cortical
microRNA biogenesis. Mol. Psychiatry 15, 1176–1189.
Beveridge, N. J., Tooney, P. A., Carroll, A. P., Gardiner, E., Bowden, N.,
Scott, R. J., Tran, N., Dedova, I..,
and Cairns, M. J. (2008). Dysregulation of miRNA 181b in the temporal
cortex in schizophrenia. Hum. Mol.
Genet. 17, 1156–1168.
Bilen, J., Liu, N., Burnett, B. G.,
Pittman, R. N., and Bonini, N.
M. (2006). MicroRNA pathways
modulate polyglutamine-induced
neurodegeneration. Mol. Cell 24,
157–163.
Boissonneault, V., Plante, I., Rivest, S.,
and Provost, P. (2009). MicroRNA298 and microRNA-328 regulate
expression of mouse beta-amyloid
precursor
protein-converting
enzyme 1. J. Biol. Chem. 284,
1971–1981.
Bonev, B., Pisco, A., and Papalopulu, N. (2011). MicroRNA-9 reveals
regional diversity of neural progenitors along the anterior-posterior
axis. Dev. Cell 20, 19–32.
Brameier, M. (2010). Genome-wide
comparative analysis of microRNAs in three non-human primates. BMC Res. Notes 3, 64.
doi:10.1186/1756-0500-3-64
Buckley, N. J., and Johnson, R. (2011).
New insights into non-coding RNA
networks in Huntington’s disease.
Exp. Neurol. 231, 191–194.
Chan, A. W., Cheng, P. H., Neumann,
A., and Yang, J. J. (2010). Reprogramming Huntington monkey skin
cells into pluripotent stem cells. Cell.
Reprogram. 12, 509–517.
Chan, A. W., Chong, K. Y., Martinovich, C., Simerly, C., and Schatten, G. (2001). Transgenic monkeys
produced by retroviral gene transfer into mature oocytes. Science 291,
309–312.
Chandrasekar, V., and Dreyer, J. L.
(2011). Regulation of MiR-124,
Let-7d, and MiR-181a in the
accumbens affects the expression,
extinction, and reinstatement of
cocaine-induced conditioned place

Frontiers in Genetics | Non-Coding RNA

services. YNPRC is supported by the National Center for Research
Resources P51RR165 and is currently supported by the Ofﬁce of
Research and Infrastructure Program (ORIP)/OD P51OD11132.
This study is supported by grant awarded by the ORIP/NIH
(RR018827) and the American Recovery and Reinvestment Act
(ARRA) Fund to Anthony W. S. Chan.
preference. Neuropsychopharmacology 36, 1149–1164.
Chekulaeva, M., and Filipowicz, W.
(2009). Mechanisms of miRNAmediated post-transcriptional regulation in animal cells. Curr. Opin.
Cell Biol. 21, 452–460.
Chekulaeva, M., Mathys, H., Zipprich, J. T., Attig, J., Colic, M.,
Parker, R., and Filipowicz, W.
(2011). miRNA repression involves
GW182-mediated recruitment of
CCR4-NOT through conserved Wcontaining motifs. Nat. Struct. Mol.
Biol. 18, 1218–1226.
Cheng, C. J., and Saltzman, W.
M. (2012). Polymer nanoparticlemediated delivery of microRNA
inhibition and alternative splicing.
Mol. Pharm.
Cheng, L. C., Pastrana, E., Tavazoie, M., and Doetsch, F. (2009).
miR-124 regulates adult neurogenesis in the subventricular zone
stem cell niche. Nat. Neurosci. 12,
399–408.
Cho, J. A., Park, H., Lim, E. H., and Lee,
K. W. (2011). MicroRNA expression
proﬁling in neurogenesis of adipose
tissue-derived stem cells. J. Genet. 90,
81–93.
Cogswell, J. P., Ward, J., Taylor, I. A.,
Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D.,
Chen, C., Prinjha, R. K., Richardson, J. C., Saunders, A. M., Roses,
A. D., and Richards, C. A. (2008).
Identiﬁcation of miRNA changes
in Alzheimer’s disease brain and
CSF yields putative biomarkers and
insights into disease pathways. J.
Alzheimers Dis. 14, 27–41.
Cole, K. A., Attiyeh, E. F., Mosse, Y.
P., Laquaglia, M. J., Diskin, S. J.,
Brodeur, G. M., and Maris, J. M.
(2008). A functional screen identiﬁes
miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol.
Cancer Res. 6, 735–742.
Connelly, C. M., Thomas, M., and
Deiters, A. (2012). High-throughput
luciferase reporter assay for smallmolecule inhibitors of microRNA
function. J. Biomol. Screen.
Crew, E., Rahman, S., Razzak-Jaffar,
A., Mott, D., Kamundi, M., Yu, G.,
Tchah, N., Lee, J., Bellavia, M., and
Zhong, C. J. (2012). MicroRNA conjugated gold nanoparticles and cell
transfection. Anal. Chem. 84, 26–29.

de Araujo, M. F., Hori, E., Maior, R.
S., Tomaz, C., Ono, T., and Nishijo,
H. (2012). Neuronal activity of the
anterior cingulate cortex during an
observation-based decision making
task in monkeys. Behav. Brain Res.
230, 48–61.
Delay, C., Calon, F., Mathews, P., Hebert,
S. S. (2011). Alzheimer-speciﬁc variants in the 3’UTR of Amyloid
precursor protein affect microRNA
function. Mol. Neurodegener. 6, 70.
Eipper-Mains, J. E., Kiraly, D. D.,
Palakodeti, D., Mains, R. E., Eipper,
B. A., and Graveley, B. R. (2011).
MicroRNA-Seq reveals cocaineregulated expression of striatal
microRNAs. RNA 17, 1529–1543.
Elmen, J., Lindow, M., Schutz, S.,
Lawrence, M., Petri, A., Obad,
S., Lindholm, M., Hedtjarn, M.,
Hansen, H. F., Berger, U., Gullans, S.,
Kearney, P., Sarnow, P., Straarup, E.
M., and Kauppinen, S. (2008). LNAmediated microRNA silencing in
non-human primates. Nature 452,
896–899.
Enciu, A. M., Popescu, B. O., and
Gheorghisan-Galateanu, A. (2012).
MicroRNAs in brain development
and degeneration. Mol. Biol. Rep. 39,
2243–2252.
Fenelon, K., Mukai, J., Xu, B., Hsu,
P. K., Drew, L. J., Karayiorgou,
M., Fischbach, G. D., Macdermott,
A. B., and Gogos, J. A. (2011).
Deﬁciency of Dgcr8, a gene disrupted by the 22q11.2 microdeletion, results in altered short-term
plasticity in the prefrontal cortex.
Proc. Natl. Acad. Sci. U.S.A. 108,
4447–4452.
Gao, F. B. (2010). Context-dependent
functions of speciﬁc microRNAs in
neuronal development. Neural Dev.
5, 25.
Gao, J., Wang, W. Y., Mao, Y. W., Graff,
J., Guan, J. S., Pan, L., Mak, G.,
Kim, D., Su, S. C., and Tsai, L. H.
(2010). A novel pathway regulates
memory and plasticity via SIRT1 and
miR-134. Nature 466, 1105–1109.
Gardiner, E., Beveridge, N. J., Wu, J.
Q., Carr, V., Scott, R. J., Tooney,
P. A., and Cairns, M. J. (2011).
Imprinted DLK1-DIO3 region of
14q32 deﬁnes a schizophreniaassociated miRNA signature in
peripheral blood mononuclear cells.
Mol. Psychiatry.

May 2012 | Volume 3 | Article 82 | 6

Chan and Kocerha

Gaughwin, P. M., Ciesla, M., Lahiri,
N., Tabrizi, S. J., Brundin, P., and
Bjorkqvist, M. (2011). Hsa-miR-34b
is a plasma-stable microRNA that
is elevated in pre-manifest Huntington’s disease. Hum. Mol. Genet. 20,
2225–2237.
Geekiyanage, H., and Chan, C. (2011).
MicroRNA-137/181c regulates serine palmitoyltransferase and in turn
amyloid beta, novel targets in sporadic Alzheimer’s disease. J. Neurosci. 31, 14820–14830.
Geekiyanage, H., Jicha, G. A., Nelson,
P. T., and Chan, C. (2011). Blood
serum miRNA: Non-invasive biomarkers for Alzheimer’s disease. Exp.
Neurol. 235, 491–496.
Gehrke, S., Imai, Y., Sokol, N., Lu,
B. (2010). Pathogenic LRRK2 negatively regulates microRNA-mediated
translational repression. Nature 466,
637–641.
Ghahramani Seno, M. M., Hu, P.,
Gwadry, F. G., Pinto, D., Marshall,
C. R., Casallo, G., and Scherer, S.
W. (2011). Gene and miRNA expression proﬁles in autism spectrum
disorders. Brain Res. 1380, 85–97.
Ghidoni, R., Benussi, L., Paterlini,
A., Albertini, V., Binetti, G., and
Emanuele, E. (2011). Cerebrospinal
ﬂuid biomarkers for Alzheimer’s disease: the present and the future.
Neurodegener. Dis. 8, 413–420.
Ghose, J., Sinha, M., Das, E., Jana,
N. R., and Bhattacharyya, N.
P. (2011). Regulation of miR146a by RelA/NFkB and p53 in
STHdh(Q111)/Hdh(Q111) cells, a
cell model of Huntington’s disease.
PLoS One 6, e23837.
Gillardon, F., Mack, M., Rist, W.,
Schnack, C., Lenter, M., Hildebrandt, T., and Hengerer, B. (2008).
MicroRNA and proteome expression proﬁling in early-symptomatic
alpha-synuclein(A30P)-transgenic
mice. Proteomics Clin. Appl. 2,
697–705.
Han, J., Denli, A. M., and Gage, F. H.
(2012). The enemy within: intronic
miR-26b represses its host gene,
ctdsp2, to regulate neurogenesis.
Genes Dev. 26, 6–10.
Haramati, S., Chapnik, E., Sztainberg,
Y., Eilam, R., Zwang, R., Gershoni,
N., McGlinn, E., Heiser, P. W.,
Wills, A. M., Wirguin, I., Rubin,
L. L., Misawa, H., Tabin, C. J.,
Brown, R. Jr., Chen, A., and Hornstein, E. (2010). miRNA malfunction causes spinal motor neuron disease. Proc. Natl. Acad. Sci. U.S.A. 107,
13111–13116.
Haramati, S., Navon, I., Issler, O.,
Ezra-Nevo, G., Gil, S., Zwang,
R., Hornstein, E., and Chen, A.

www.frontiersin.org

MicroRNAs in neuropsychiatry and neurodegeneration

(2011). MicroRNA as repressors of
stress-induced anxiety: the case of
amygdalar miR-34. J. Neurosci. 31,
14191–14203.
Havelda, Z. (2010). In situ detection of
miRNAs using LNA probes. Methods
Mol. Biol. 592, 127–136.
He, Y., Yang, C., Kirkmire, C. M.,
and Wang, Z. J. (2010). Regulation of opioid tolerance by let7 family microRNA targeting the
mu opioid receptor. J. Neurosci. 30,
10251–10258.
Hebert, S. S., and De Strooper, B. (2009).
Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 32, 199–206.
Hebert, S. S., Horre, K., Nicolai, L.,
Bergmans, B., Papadopoulou, A. S.,
Delacourte, A., and De Strooper,
B. (2009). MicroRNA regulation of
Alzheimer’s amyloid precursor protein expression. Neurobiol. Dis. 33,
422–428.
Hebert, S. S., Horre, K., Nicolai,
L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N.,
Kauppinen, S., Delacourte, A., and
De Strooper, B. (2008). Loss of
microRNA cluster miR-29a/b-1 in
sporadic Alzheimer’s disease correlates with increased BACE1/betasecretase expression. Proc. Natl.
Acad. Sci. U.S.A. 105, 6415–6420.
Hollander, J. A., Im, H. I., Amelio,
A. L., Kocerha, J., Bali, P., Lu, Q.,
Willoughby, D., Wahlestedt, C.,
Conkright, M. D., and Kenny,
P. J. (2010). Striatal microRNA
controls cocaine intake through
CREB signalling. Nature 466,
197–202.
Hu, H. Y., Guo, S., Xi, J., Yan, Z.,
Fu, N., Zhang, X., Menzel, C.,
Liang, H., Yang, H., Zhao, M.,
Zeng, R., Chen, W., Paabo, S., and
Khaitovich, P. (2011). MicroRNA
expression and regulation in
human, chimpanzee, and macaque
brains. PLoS Genet. 7, e1002327.
doi:10.1371/journal.pgen. 1002327
Hunsberger, J. G., Austin, D. R., Chen,
G., and Manji, H. K. (2009). MicroRNAs in mental health: from biological underpinnings to potential
therapies. Neuromolecular Med. 11,
173–182.
Hwang do, W., Son, S., Jang, J., Youn,
H., Lee, S., Lee, D., Lee, Y. S.,
Jeong, J. M., Kim, W. J., and Lee,
D. S. (2011). A brain-targeted rabies
virus glycoprotein-disulﬁde linked
PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 32,
4968–4975.
Im, H. I., Hollander, J. A., Bali, P., and
Kenny, P. J. (2010). MeCP2 controls BDNF expression and cocaine

intake through homeostatic interactions with microRNA-212. Nat.
Neurosci. 13, 1120–1127.
Insel, T. R. (2009). Translating scientiﬁc opportunity into public health
impact: a strategic plan for research
on mental illness. Arch. Gen. Psychiatry 66, 128–133.
Jiao, J., Herl, L. D., Farese, R. V., and Gao,
F. B. (2010). MicroRNA-29b regulates the expression level of human
progranulin, a secreted glycoprotein implicated in frontotemporal
dementia. PLoS ONE 5, e10551.
doi:10.1371/journal.pone.0010551
Jin, H., Yu, Y., Chrisler, W. B., Xiong,
Y., Hu, D., and Lei, C. (2012).
Delivery of microRNA-10b with
polylysine nanoparticles for inhibition of breast cancer cell wound
healing. Breast Cancer (Auckl.) 6,
9–19.
Jin, P., Zarnescu, D. C., Ceman, S.,
Nakamoto, M., Mowrey, J., Jongens,
T. A., Nelson, D. L., Moses, K., and
Warren, S. T. (2004). Biochemical
and genetic interaction between the
fragile X mental retardation protein
and the microRNA pathway. Nat.
Neurosci. 7, 113–117.
Johnson, R., Zuccato, C., Belyaev, N.
D., Guest, D. J., Cattaneo, E., and
Buckley, N. J. (2008). A microRNAbased gene dysregulation pathway in
Huntington’s disease. Neurobiol. Dis.
29, 438–445.
Juhila, J., Sipila, T., Icay, K., Nicorici,
D., Ellonen, P., Kallio, A., Korpelainen, E., Greco, D., and Hovatta, I. (2011). MicroRNA expression
proﬁling reveals miRNA families
regulating speciﬁc biological pathways in mouse frontal cortex and
hippocampus. PLoS ONE 6, e21495.
doi:10.1371/journal.pone.0021495
Junn, E., Lee, K. W., Jeong, B.
S., Chan, T. W., Im, J. Y., and
Mouradian, M. M. (2009). Repression of alpha-synuclein expression and toxicity by microRNA-7.
Proc. Natl. Acad. Sci. U.S.A. 106,
13052–13057.
Kao, W. T., Wang, Y., Kleinman, J.
E., Lipska, B. K., Hyde, T. M.,
Weinberger, D. R., and Law, A. J.
(2010). Common genetic variation
in Neuregulin 3 (NRG3) inﬂuences
risk for schizophrenia and impacts
NRG3 expression in human brain.
Proc. Natl. Acad. Sci. U.S.A. 107,
15619–15624.
Kapsimali, M., Kloosterman, W. P.,
de Bruijn, E., Rosa, F., Plasterk,
R. H., and Wilson, S. W. (2007).
MicroRNAs show a wide diversity of
expression proﬁles in the developing
and mature central nervous system.
Genome Biol. 8, R173.

Kim, A. H., Reimers, M., Maher,
B., Williamson, V., McMichael, O.,
McClay, J. L., van den Oord, E.
J., Riley, B. P., Kendler, K. S., and
Vladimirov, V. I. (2010). MicroRNA
expression proﬁling in the prefrontal
cortex of individuals affected with
schizophrenia and bipolar disorders.
Schizophr. Res. 124, 183–191.
Kim, H., Lee, G., Ganat, Y., Papapetrou,
E. P., Lipchina, I., Socci, N. D., Sadelain, M., and Studer, L. (2011). miR371-3 expression predicts neural differentiation propensity in human
pluripotent stem cells. Cell Stem Cell
8, 695–706.
Kim, J., Inoue, K., Ishii, J., Vanti, W. B.,
Voronov, S. V., Murchison, E., Hannon, G., and Abeliovich, A. (2007). A
MicroRNA feedback circuit in midbrain dopamine neurons. Science
317, 1220–1224.
King, M. C., and Wilson, A. C.
(1975). Evolution at two levels in
humans and chimpanzees. Science
188, 107–116.
Kocerha, J., Faghihi, M. A., LopezToledano, M. A., Huang, J., Ramsey,
A. J., Caron, M. G., Sales, N.,
Willoughby, D., Elmen, J., Hansen,
H. F., Orum, H., Kauppinen, S.,
Kenny, P. J., and Wahlestedt, C.
(2009). MicroRNA-219 modulates NMDA receptor-mediated
neurobehavioral
dysfunction.
Proc. Natl. Acad. Sci. U.S.A. 106,
3507–3512.
Kocerha, J., Kouri, N., Baker, M., Finch,
N., DeJesus-Hernandez, M., Gonzalez, J., Chidamparam, K., Josephs,
K. A., Boeve, B. F., Graff-Radford,
N. R., Crook, J., Dickson, D. W.,
and Rademakers, R. (2011). Altered
microRNA expression in frontotemporal lobar degeneration with TDP43 pathology caused by progranulin
mutations. BMC Genomics 12, 527.
doi:10.1186/1471-2164-12-527
Konopka, W., Kiryk, A., Novak, M., Herwerth, M., Parkitna, J. R., Wawrzyniak, M., Kowarsch, A., Michaluk,
P., Dzwonek, J., Arnsperger, T.,
Wilczynski, G., Merkenschlager, M.,
Theis, F. J., Kohr, G., Kaczmarek, L.,
and Schutz, G. (2010). MicroRNA
loss enhances learning and memory in mice. J. Neurosci. 30,
14835–14842.
Lai, C. Y., Yu, S. L., Hsieh, M. H.,
Chen, C. H., Chen, H. Y., Wen,
C. C., Huang, Y. H., Hsiao, P. C.,
Hsiao, C. K., Liu, C. M., Yang, P.
C., Hwu, H. G., and Chen, W. J.
(2011). MicroRNA expression aberration as potential peripheral blood
biomarkers for schizophrenia. PLoS
ONE 6, e21635. doi:10.1371/journal.pone.0021635

May 2012 | Volume 3 | Article 82 | 7

Chan and Kocerha

Lanford, R. E., Hildebrandt-Eriksen, E.
S., Petri, A., Persson, R., Lindow,
M., Munk, M. E., Kauppinen, S.,
and Orum, H. (2010). Therapeutic
silencing of microRNA-122 in primates with chronic hepatitis C virus
infection. Science 327, 198–201.
Lau, P., and de Strooper, B. (2010). Dysregulated microRNAs in neurodegenerative disorders. Semin. Cell
Dev. Biol. 21, 768–773.
Lee, S. T., Chu, K., Im, W. S., Yoon, H.
J., Im, J. Y., Park, J. E., Park, K. H.,
Jung, K. H., Lee, S. K., Kim, M., and
Roh, J. K. (2011). Altered microRNA
regulation in Huntington’s disease
models. Exp. Neurol. 227, 172–179.
Li, Y., Lin, L., and Jin, P. (2008). The
microRNA pathway and fragile X
mental retardation protein. Biochim.
Biophys. Acta 1779, 702–705.
Li, Y. Y., Cui, J. G., Hill, J. M., Bhattacharjee, S., Zhao, Y., and Lukiw,
W. J. (2011). Increased expression of
miRNA-146a in Alzheimer’s disease
transgenic mouse models. Neurosci.
Lett. 487, 94–98.
Liu, N., Landreh, M., Cao, K., Abe, M.,
Hendriks, G. J., Kennerdell, J. R.,
Zhu, Y., Wang, L. S., and Bonini, N.
M. (2012a). The microRNA miR-34
modulates ageing and neurodegeneration in Drosophila. Nature 482,
519–523.
Liu, W., Liu, C., Zhu, J., Shu, P., Yin,
B., Gong, Y., Qiang, B., Yuan, J.,
and Peng, X. (2012b). MicroRNA16 targets amyloid precursor protein
to potentially modulate Alzheimer’sassociated pathogenesis in SAMP8
mice. Neurobiol. Aging 33, 522–534.
Long, J. M., and Lahiri, D. K.
(2011). MicroRNA-101 downregulates Alzheimer’s amyloid-beta precursor protein levels in human
cell cultures and is differentially
expressed. Biochem. Biophys. Res.
Commun. 404, 889–895.
Lukiw, W. J. (2007). Micro-RNA speciation in fetal, adult and Alzheimer’s
disease hippocampus. Neuroreport
18, 297–300.
Magill, S. T., Cambronne, X. A., Luikart,
B. W., Lioy, D. T., Leighton, B. H.,
Westbrook, G. L., Mandel, G., and
Goodman, R. H. (2010). microRNA132 regulates dendritic growth and
arborization of newborn neurons in
the adult hippocampus. Proc. Natl.
Acad. Sci. U.S.A. 107, 20382–20387.
Mallick, B., and Ghosh, Z. (2011).
A complex crosstalk between polymorphic microRNA target sites and
AD prognosis. RNA Biol. 8, 665–673.
Margis, R., and Rieder, C. R. (2011).
Identiﬁcation of blood microRNAs
associated to Parkinsonis disease. J.
Biotechnol. 152, 96–101.

MicroRNAs in neuropsychiatry and neurodegeneration

Marti, E., Pantano, L., Banez-Coronel,
M., Llorens, F., Minones-Moyano,
E., Porta, S., Sumoy, L., Ferrer, I.,
and Estivill, X. (2010). A myriad of miRNA variants in control and Huntington’s disease brain
regions detected by massively parallel sequencing. Nucleic Acids Res. 38,
7219–7235.
Martins, M., Rosa, A., Guedes, L.
C., Fonseca, B. V., Gotovac, K.,
Violante, S., Mestre, T., Coelho,
M., Rosa, M. M., Martin, E. R.,
Vance, J. M., Outeiro, T. F., Wang,
L., Borovecki, F., Ferreira, J. J.,
and Oliveira, S. A. (2011). Convergence of miRNA expression proﬁling, alpha-synuclein interaction and
GWAS in Parkinson’s disease. PLoS
ONE 6, e25443. doi:10.1371/journal.pone.0025443
McConkey, E. H., and Varki, A.
(2000). A primate genome project
deserves high priority. Science 289,
1295–1296.
Mellios, N., Sugihara, H., Castro, J.,
Banerjee, A., Le, C., Kumar, A., Crawford, B., Strathmann, J., Tropea, D.,
Levine, S. S., Edbauer, D., and Sur,
M. (2011). miR-132, an experiencedependent microRNA, is essential
for visual cortex plasticity. Nat. Neurosci. 14, 1240–1242.
Minones-Moyano, E., Porta, S.,
Escaramis, G., Rabionet, R., Iraola,
S., Kagerbauer, B., Espinosa-Parrilla,
Y., Ferrer, I., Estivill, X., and Marti,
E. (2011). MicroRNA proﬁling of
Parkinson’s disease brains identiﬁes
early downregulation of miR-34b/c
which modulate mitochondrial
function. Hum. Mol. Genet. 20,
3067–3078.
Montgomery, R. L., and van Rooij,
E. (2011). Therapeutic advances in
MicroRNA targeting. J. Cardiovasc.
Pharmacol. 57, 1–7.
Moreau, M. P., Bruse, S. E., David-Rus,
R., Buyske, S., and Brzustowicz, L. M.
(2011). Altered microRNA expression proﬁles in postmortem brain
samples from individuals with schizophrenia and bipolar disorder. Biol.
Psychiatry 69, 188–193.
Mouillet-Richard, S., Baudry, A., Launay, J. M., and Kellermann, O.
(2011). MicroRNAs and depression.
Neurobiol. Dis. 46, 272–278.
Mouradian, M. M. (2012). MicroRNAs
in Parkinson’s disease. Neurobiol.
Dis. 46, 279–284.
Nelson, P. T., and Wang, W. X. (2010).
MiR-107 is reduced in Alzheimer’s
disease brain neocortex: validation
study. J. Alzheimers Dis. 21, 75–79.
Nunez-Iglesias, J., Liu, C. C., Morgan,
T. E., Finch, C. E., and Zhou, X. J.
(2010). Joint genome-wide proﬁling

Frontiers in Genetics | Non-Coding RNA

of miRNA and mRNA expression
in Alzheimer’s disease cortex reveals
altered miRNA regulation. PLoS
ONE 5, e8898. doi:10.1371/journal.pone.0008898
Obad, S., dos Santos, C. O., Petri, A.,
Heidenblad, M., Broom, O., Ruse,
C., Fu, C., Lindow, M., Stenvang,
J., Straarup, E. M., Hansen, H. F.,
Koch, T., Pappin, D., Hannon, G. J.,
and Kauppinen, S. (2011). Silencing of microRNA families by seedtargeting tiny LNAs. Nat. Genet. 43,
371–378.
O’Connor, R. M., Dinan, T. G., and
Cryan, J. F. (2011). Little things on
which happiness depends: microRNAs as novel therapeutic targets for
the treatment of anxiety and depression. Mol. Psychiatry 17, 359–376.
Paabo, S. (2001). Genomics and society.
The human genome and our view of
ourselves. Science 291, 1219–1220.
Packer, A. N., Xing, Y., Harper, S.
Q., Jones, L., and Davidson, B. L.
(2008). The bifunctional microRNA
miR-9/miR-9∗ regulates REST and
CoREST and is downregulated in
Huntington’s disease. J. Neurosci. 28,
14341–14346.
Park, J. E., Heo, I., Tian, Y., Simanshu,
D. K., Chang, H., Jee, D., Patel, D. J.,
and Kim, V. N. (2011). Dicer recognizes the 5’ end of RNA for efﬁcient
and accurate processing. Nature 475,
201–205.
Patel, N., Hoang, D., Miller, N., Ansaloni, S., Huang, Q., Rogers, J. T., Lee,
J. C., and Saunders, A. J. (2008).
MicroRNAs can regulate human
APP levels. Mol. Neurodegener. 3, 10.
Perkins, D. O., Jeffries, C. D., Jarskog,
L. F., Thomson, J. M., Woods, K.,
Newman, M. A., Parker, J. S., Jin,
J., and Hammond, S. M. (2007).
microRNA expression in the prefrontal cortex of individuals with
schizophrenia and schizoaffective
disorder. Genome Biol. 8, R27.
Perkins, T., Stokes, M., McGillivray, J.,
and Bittar, R. (2010). Mirror neuron dysfunction in autism spectrum disorders. J. Clin. Neurosci. 17,
1239–1243.
Persengiev, S. P., Kondova, II, and Bontrop, R. E. (2012). The impact of
microRNAs on brain aging and
neurodegeneration. Curr. Gerontol.
Geriatr. Res. 2012, 359369.
Petri, A., Lindow, M., and Kauppinen,
S. (2009). MicroRNA silencing in
primates: towards development of
novel therapeutics. Cancer Res. 69,
393–395.
Pietrzykowski, A. Z., Friesen, R. M.,
Martin, G. E., Puig, S. I., Nowak,
C. L., Wynne, P. M., Siegelmann,
H. T., and Treistman, S. N. (2008).

Posttranscriptional regulation of BK
channel splice variant stability by
miR-9 underlies neuroadaptation to
alcohol. Neuron 59, 274–287.
Rademakers, R., Eriksen, J. L., Baker,
M., Robinson, T., Ahmed, Z., Lincoln, S. J., Finch, N., Rutherford, N.
J., Crook, R. J., Josephs, K. A., Boeve,
B. F., Knopman, D. S., Petersen, R.
C., Parisi, J. E., Caselli, R. J., Wszolek,
Z. K., Uitti, R. J., Feldman, H., Hutton, M. L., Mackenzie, I. R., GraffRadford, N. R., and Dickson, D.
W. (2008). Common variation in
the miR-659 binding-site of GRN
is a major risk factor for TDP43positive frontotemporal dementia.
Hum. Mol. Genet. 17, 3631–3642.
Rajasethupathy, P., Fiumara, F., Sheridan, R., Betel, D., Puthanveettil, S.
V., Russo, J. J., Sander, C., Tuschl,
T., and Kandel, E. (2009). Characterization of small RNAs in Aplysia
reveals a role for miR-124 in constraining synaptic plasticity through
CREB. Neuron 63, 803–817.
Remenyi, J., Hunter, C. J., Cole, C.,Ando,
H., Impey, S., Monk, C. E., Martin, K.
J., Barton, G. J., Hutvagner, G., and
Arthur, J. S. (2010). Regulation of
the miR-212/132 locus by MSK1 and
CREB in response to neurotrophins.
Biochem. J. 428, 281–291.
Richardson, K., Lai, C. Q., Parnell,
L. D., Lee, Y. C., and Ordovas, J.
M. (2011). A genome-wide survey
for SNPs altering microRNA seed
sites identiﬁes functional candidates
in GWAS. BMC Genomics 12, 504.
doi:10.1186/1471-2164-12-504
Ripke, S., Sanders, A. R., Kendler, K. S.,
Levinson, D. F., Sklar, P., Holmans,
P. A., Lin, D. Y., Duan, J., Ophoff,
R. A., Andreassen, O. A., Scolnick,
E., Cichon, S., St Clair, D., Corvin,
A., Gurling, H., Werge, T., Rujescu,
D., Blackwood, D. H., Pato, C. N.,
Malhotra, A. K., Purcell, S., Dudbridge, F., Neale, B. M., Rossin, L.,
Visscher, P. M., Posthuma, D., Ruderfer, D. M., Fanous, A., Stefansson, H.,
Steinberg, S., Mowry, B. J., Golimbet,
V., De Hert, M., Jonsson, E. G., Bitter, I., Pietilainen, O. P., Collier, D.
A., Tosato, S., Agartz, I., Albus, M.,
Alexander, M., Amdur, R. L., Amin,
F., Bass, N., Bergen, S. E., Black,
D. W., Borglum, A. D., Brown, M.
A., Bruggeman, R., Buccola, N. G.,
Byerley, W. F., Cahn, W., Cantor, R.
M., Carr, V. J., Catts, S. V., Choudhury, K., Cloninger, C. R., Cormican, P., Craddock, N., Danoy, P. A.,
Datta, S., de Haan, L., Demontis, D.,
Dikeos, D., Djurovic, S., Donnelly,
P., Donohoe, G., Duong, L., Dwyer,
S., Fink-Jensen, A., Freedman, R.,
Freimer, N. B., Friedl, M., Georgieva,

May 2012 | Volume 3 | Article 82 | 8

Chan and Kocerha

L., Giegling, I., Gill, M., Glenthoj, B., Godard, S., Hamshere, M.,
Hansen, M., Hansen, T., Hartmann,
A. M., Henskens, F. A., Hougaard,
D. M., Hultman, C. M., Ingason,
A., Jablensky, A. V., Jakobsen, K.
D., Jay, M., Jurgens, G., Kahn, R.
S., Keller, M. C., Kenis, G., Kenny,
E., Kim, Y., Kirov, G. K., Konnerth,
H., Konte, B., Krabbendam, L., Krasucki, R., Lasseter, V. K., Laurent, C.,
Lawrence, J., Lencz, T., Lerer, F. B.,
Liang, K. Y., Lichtenstein, P., Lieberman, J. A., Linszen, D. H., Lonnqvist,
J., Loughland, C. M., Maclean, A. W.,
Maher, B. S., Maier, W., Mallet, J.,
Malloy, P., Mattheisen, M., Mattingsdal, M., McGhee, K. A., McGrath,
J. J., McIntosh, A., McLean, D. E.,
McQuillin, A., Melle, I., Michie, P. T.,
Milanova, V., Morris, D. W., Mors,
O., Mortensen, P. B., Moskvina, V.,
Muglia, P., Myin-Germeys, I., Nertney, D. A., Nestadt, G., Nielsen, J.,
Nikolov, I., Nordentoft, M., Norton,
N., Nothen, M. M., O’Dushlaine,
C. T., Olincy, A., Olsen, L., O’Neill,
F. A., Orntoft, T. F., Owen, M. J.,
Pantelis, C., Papadimitriou, G., Pato,
M. T., Peltonen, L., Petursson, H.,
Pickard, B., Pimm, J., Pulver, A. E.,
Puri, V., Quested, D., Quinn, E. M.,
Rasmussen, H. B., Rethelyi, J. M.,
Ribble, R., Rietschel, M., Riley, B.
P., Ruggeri, M., Schall, U., Schulze,
T. G., Schwab, S. G., Scott, R. J.,
Shi, J., Sigurdsson, E., Silverman, J.
M., Spencer, C. C., Stefansson, K.,
Strange, A., Strengman, E., Stroup, T.
S., Suvisaari, J., Terenius, L., Thirumalai, S., Thygesen, J. H., Timm, S.,
Toncheva, D., van den Oord, E., van
Os, J., van Winkel, R., Veldink, J.,
Walsh, D., Wang, A. G., Wiersma, D.,
Wildenauer, D. B., Williams, H. J.,
Williams, N. M., Wormley, B., Zammit, S., Sullivan, P. F., O’Donovan,
M. C., Daly, M. J., and Gejman,
P. V. (2011). Genome-wide association study identiﬁes ﬁve new
schizophrenia loci. Nat. Genet. 43,
969–976.
Ruberti, F., Barbato, C., and Cogoni,
C. (2011). Targeting microRNAs in
neurons: tools and perspectives. Exp.
Neurol. 235, 419–426.
Saba, R., Storchel, P. H., Aksoy-Aksel, A.,
Kepura, F., Lippi, G., Plant, T. D., and
Schratt, G. M. (2012). Dopamineregulated microRNA MiR-181a controls GluA2 surface expression in
hippocampal neurons. Mol. Cell.
Biol. 32, 619–632.
Santarelli, D. M., Beveridge, N. J.,
Tooney, P. A., and Cairns, M. J.
(2011). Upregulation of dicer and
microRNA expression in the dorsolateral prefrontal cortex Brodmann

www.frontiersin.org

MicroRNAs in neuropsychiatry and neurodegeneration

area 46 in schizophrenia. Biol. Psychiatry 69, 180–187.
Sarachana, T., Zhou, R., Chen, G.,
Manji, H. K., and Hu, V. W. (2010).
Investigation of post-transcriptional
gene regulatory networks associated
with autism spectrum disorders by
microRNA expression proﬁling of
lymphoblastoid cell lines. Genome
Med. 2, 23.
Saus, E., Soria, V., Escaramis, G.,
Vivarelli, F., Crespo, J. M., Kagerbauer, B., Menchon, J. M., Urretavizcaya, M., Gratacos, M., and Estivill,
X. (2010). Genetic variants and
abnormal processing of pre-miR182, a circadian clock modulator,
in major depression patients with
late insomnia. Hum. Mol. Genet. 19,
4017–4025.
Schipper, H. M., Maes, O. C.,
Chertkow, H. M., and Wang, E.
(2007). MicroRNA expression in
Alzheimer blood mononuclear
cells. Gene Regul. Syst. Bio. 1,
263–274.
Schoﬁeld, C. M., Hsu, R., Barker, A. J.,
Gertz, C. C., Blelloch, R., and Ullian,
E. M. (2011). Monoallelic deletion
of the microRNA biogenesis gene
Dgcr8 produces deﬁcits in the development of excitatory synaptic transmission in the prefrontal cortex.
Neural Dev. 6, 11.
Schonrock, N., Ke, Y. D., Humphreys,
D., Staufenbiel, M., Ittner, L. M.,
Preiss, T., and Gotz, J. (2010).
Neuronal microRNA deregulation
in response to Alzheimer’s disease
amyloid-beta. PLoS ONE 5, e11070.
doi:10.1371/journal.pone.0011070
Seto, A. G. (2010). The road toward
microRNA therapeutics. Int. J.
Biochem. Cell Biol. 42, 1298–1305.
Shaltiel, G., Hanan, M., Wolf, Y., Barbash, S., Kovalev, E., Shoham, S.,
and Soreq, H. (2012). Hippocampal microRNA-132 mediates stressinducible cognitive deﬁcits through
its acetylcholinesterase target. Brain
Struct. Funct.
Shi, S. J., Zhong, Z. R., Liu, J.,
Zhang, Z. R., Sun, X., and Gong,
T. (2012). Solid lipid nanoparticles loaded with anti-microRNA
oligonucleotides (AMOs) for suppression of microRNA-21 functions
in human lung cancer cells. Pharm.
Res. 29, 97–109.
Shi, Y., Zhao, X., Hsieh, J., Wichterle,
H., Impey, S., Banerjee, S., Neveu, P.,
and Kosik, K. S. (2010). MicroRNA
regulation of neural stem cells
and neurogenesis. J. Neurosci. 30,
14931–14936.
Shibata, M., Kurokawa, D., Nakao,
H., Ohmura, T., and Aizawa,
S. (2008). MicroRNA-9 modulates

Cajal-Retzius cell differentiation by
suppressing Foxg1 expression in
mouse medial pallium. J. Neurosci.
28, 10415–10421.
Shibata, M., Nakao, H., Kiyonari, H.,
Abe, T., and Aizawa, S. (2011).
MicroRNA-9 regulates neurogenesis in mouse telencephalon
by targeting multiple transcription factors. J. Neurosci. 31,
3407–3422.
Shioya, M., Obayashi, S., Tabunoki,
H., Arima, K., Saito, Y., Ishida,
T., and Satoh, J. (2010). Aberrant
microRNA expression in the brains
of neurodegenerative diseases: miR29a decreased in Alzheimer disease
brains targets neurone navigator 3.
Neuropathol. Appl. Neurobiol. 36,
320–330.
Sinha, M., Ghose, J., Das, E.,
and
Bhattarcharyya,
N.
P.
(2010). Altered microRNAs in
STHdh(Q111)/Hdh(Q111)
cells:
miR-146a targets TBP. Biochem.
Biophys. Res. Commun. 396,
742–747.
Smalheiser, N. R., Lugli, G., Rizavi,
H. S., Torvik, V. I., Turecki, G.,
and Dwivedi, Y. (2012). MicroRNA
expression is down-regulated and
reorganized in prefrontal cortex of
depressed suicide subjects. PLoS One
7, e33201.
Smith, P. Y., Delay, C., Girard, J.,
Papon, M. A., Planel, E., Sergeant,
N., Buee, L., and Hebert, S. S.
(2011). MicroRNA-132 loss is associated with tau exon 10 inclusion
in progressive supranuclear palsy.
Hum. Mol. Genet. 20, 4016–4024.
Stenvang, J., Silahtaroglu, A. N.,
Lindow, M., Elmen, J., and Kauppinen, S. (2008). The utility
of LNA in microRNA-based
cancer diagnostics and therapeutics. Semin. Cancer Biol. 18,
89–102.
Sun, G., Yan, J., Noltner, K., Feng,
J., Li, H., Sarkis, D. A., Sommer, S. S., and Rossi, J. J. (2009).
SNPs in human miRNA genes affect
biogenesis and function. RNA 15,
1640–1651.
Tal, T. L., Franzosa, J. A., Tilton, S.
C., Philbrick, K. A., Iwaniec, U. T.,
Turner, R. T., Waters, K. M., and Tanguay, R. L. (2012). MicroRNAs control neurobehavioral development
and function in zebraﬁsh. FASEB J.
Tao, J., Wu, H., Lin, Q., Wei, W., Lu, X.
H., Cantle, J. P., Ao, Y., Olsen, R. W.,
Yang, X. W., Mody, I., Sofroniew, M.
V., and Sun, Y. E. (2011). Deletion
of astroglial Dicer causes non-cellautonomous neuronal dysfunction
and degeneration. J. Neurosci. 31,
8306–8319.

Thompson, W. K., Hallmayer, J., and
O’Hara, R. (2011). Design considerations for characterizing psychiatric trajectories across the lifespan: application to effects of APOEepsilon4 on cerebral cortical thickness in Alzheimer’s disease. Am. J.
Psychiatry 168, 894–903.
Vo, N., Klein, M. E., Varlamova,
O., Keller, D. M., Yamamoto, T.,
Goodman, R. H., and Impey, S.
(2005). A cAMP-response element
binding protein-induced microRNA
regulates neuronal morphogenesis.
Proc. Natl. Acad. Sci. U.S.A. 102,
16426–16431.
Waber, D. P., Forbes, P. W., Almli, C.
R., and Blood, E. A. (2012). Fouryear longitudinal performance of a
population-based sample of healthy
children on a neuropsychological
battery: The NIH MRI Study of
normal brain development. J. Int.
Neuropsychol. Soc. 18, 179–190.
Wang, H., Liu, J., Zong, Y., Xu, Y., Deng,
W., Zhu, H., Liu, Y., Ma, C., Huang,
L., Zhang, L., and Qin, C. (2010).
miR-106b aberrantly expressed in a
double transgenic mouse model for
Alzheimer’s disease targets TGF-beta
type II receptor. Brain Res. 1357,
166–174.
Wang, W. X., Huang, Q., Hu, Y.,
Stromberg, A. J., and Nelson, P.
T. (2011). Patterns of microRNA
expression in normal and early
Alzheimer’s disease human temporal
cortex: white matter versus gray matter. Acta Neuropathol. 121, 193–205.
Wang, W. X., Rajeev, B. W., Stromberg,
A. J., Ren, N., Tang, G., Huang, Q.,
Rigoutsos, I., Nelson, P. T. (2008).
The expression of microRNA miR107 decreases early in Alzheimer’s
disease and may accelerate disease
progression through regulation of
beta-site amyloid precursor proteincleaving enzyme 1. J. Neurosci. 28,
1213–1223.
Wang, W. X., Wilfred, B. R., Madathil,
S. K., Tang, G., Hu, Y., Dimayuga,
J., Stromberg, A. J., Huang, Q.,
Saatman, K. E., and Nelson, P.
T. (0000). miR-107 regulates granulin/progranulin with implications
for traumatic brain injury and neurodegenerative disease. Am. J. Pathol.
177, 334–345.
Wang, X., Liu, P., Zhu, H., Xu, Y.,
Ma, C., Dai, X., Huang, L., Liu, Y.,
Zhang, L., and Qin, C. (2009). miR34a, a microRNA up-regulated in
a double transgenic mouse model
of Alzheimer’s disease, inhibits bcl2
translation. Brain Res. Bull. 80,
268–273.
Williams, A. H., Valdez, G., Moresi, V.,
Qi, X., McAnally, J., Elliott, J. L.,

May 2012 | Volume 3 | Article 82 | 9

Chan and Kocerha

Bassel-Duby, R., Sanes, J. R., and
Olson, E. N. (2009). MicroRNA206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 326,
1549–1554.
Xu, Y., Li, F., Zhang, B., Zhang, K.,
Zhang, F., Huang, X., Sun, N., Ren,Y.,
Sui, M., and Liu, P. (2010a). MicroRNAs and target site screening reveals
a pre-microRNA-30e variant associated with schizophrenia. Schizophr.
Res. 119, 219–227.
Xu, Y., Liu, H., Li, F., Sun, N., Ren, Y.,
Liu, Z., Cao, X., Wang, Y., Liu, P.,
and Zhang, K. (2010b). A polymorphism in the microRNA-30e precursor associated with major depressive
disorder risk and P300 waveform. J.
Affect. Disord. 127, 332–336.
Yang, R., Dai, Z., Chen, S., and Chen, L.
(2011). MicroRNA-mediated gene
regulation plays a minor role
in the transcriptomic plasticity
of cold-acclimated zebraﬁsh brain
tissue. BMC Genomics 12, 605.
doi:10.1186/1471-2164-12-605

MicroRNAs in neuropsychiatry and neurodegeneration

Yang, S. H., Cheng, P. H., Banta, H.,
Piotrowska-Nitsche, K., Yang, J. J.,
Cheng, E. C., Snyder, B., Larkin,
K., Liu, J., Orkin, J., Fang, Z. H.,
Smith, Y., Bachevalier, J., Zola, S.
M., Li, S. H., Li, X. J., and Chan,
A. W. (2008). Towards a transgenic
model of Huntington’s disease in
a non-human primate. Nature 453,
921–924.
Yang, Y., Xu, S., Xia, L., Wang, J., Wen,
S., Jin, P., and Chen, D. (2009).
The bantam microRNA is associated with drosophila fragile X mental retardation protein and regulates the fate of germline stem
cells. PLoS Genet. 5, e1000444.
doi:10.1371/journal.pgen.1000444
Yao, J., Hennessey, T., Flynt, A., Lai,
E., Beal, M. F., Lin, M. T. (2010).
MicroRNA-related coﬁlin abnormality in Alzheimer’s disease. PLoS
One 5:e15546.
Zhang, X. Y., Yang, Z. Y., Li, J. M., Li,
H. X., Wang, L., Gong, Q. Y., and
Zhou, D. (2012). Longitudinal (1)
H MRS assessment of the thalamus

Frontiers in Genetics | Non-Coding RNA

in a Coriaria lactone-induced rhesus
monkey status epilepticus model.
NMR Biomed.
Zhou, R., Yuan, P., Wang, Y., Hunsberger, J. G., Elkahloun, A., Wei,
Y., Damschroder-Williams, P., Du,
J., Chen, G., and Manji, H.
K. (2009). Evidence for selective microRNAs and their effectors as common long-term targets
for the actions of mood stabilizers. Neuropsychopharmacology 34,
1395–1405.
Zhu, Y., Kalbﬂeisch, T., Brennan, M.
D., and Li, Y. (2009). A MicroRNA
gene is hosted in an intron of
a schizophrenia-susceptibility gene.
Schizophr. Res. 109, 86–89.
Zovoilis, A., Agbemenyah, H. Y., AgisBalboa, R. C., Stilling, R. M.,
Edbauer, D., Rao, P., Farinelli,
L., Delalle, I., Schmitt, A., Falkai,
P., Bahari-Javan, S., Burkhardt, S.,
Sananbenesi, F., Fischer, A. (2011).
MicroRNA-34c is a novel target
to treat dementias. EMBO J 30,
4299–4308.

Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that
could be construed as a potential conﬂict of interest.
Received: 20 March 2012; paper pending published: 10 April 2012; accepted:
26 April 2012; published online: 17 May
2012.
Citation: Chan AWS and Kocerha J
(2012) The path to microRNA therapeutics in psychiatric and neurodegenerative disorders. Front. Gene. 3:82. doi:
10.3389/fgene.2012.00082
This article was submitted to Frontiers in
Non-Coding RNA, a specialty of Frontiers
in Genetics.
Copyright © 2012 Chan and Kocerha.
This is an open-access article distributed
under the terms of the Creative Commons
Attribution Non Commercial License,
which permits non-commercial use, distribution, and reproduction in other
forums, provided the original authors and
source are credited.

May 2012 | Volume 3 | Article 82 | 10

